Avidity Biosciences Earnings Reports

Avidity Biosciences reported successful readouts from its three clinical-stage programs in 2024, demonstrating the consistent and reproducible data of its AOC platform. The company is planning to submit its first BLA for an AOC and prepare for three potential successive product launches. With a strong balance sheet of approximately $1.5 billion, Avidity is expediting its global commercial infrastructure development and expanding its team.

Avidity Biosciences reported positive del-zota data, initiated the biomarker cohort for the del-brax FORTITUDE study, and is on track with enrollment in the global Phase 3 HARBOR study for del-desiran. The company's cash position is approximately $1.6 billion.

Avidity Biosciences reported positive clinical trial data for del-zota and del-brax, initiated the global Phase 3 HARBOR™ trial for del-desiran, and plans to announce its lead precision cardiology program target in Q4 2024. The company's cash position at the end of the second quarter was approximately $1.3 billion.

Avidity Biosciences reported a cash position of $915.9 million at the end of Q1 2024, following a $400 million private placement. They are advancing their AOC platform and plan to initiate the global Phase 3 HARBOR™ study for del-desiran this quarter. Collaboration revenue was $3.5 million, and research and development expenses were $66.8 million.